Format

Send to

Choose Destination
Neurobiol Dis. 2013 Aug;56:6-13. doi: 10.1016/j.nbd.2013.04.003. Epub 2013 Apr 10.

RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Author information

1
Department of the Neuroscience Training Program, University of Iowa, Iowa City, IA 52242, USA.

Abstract

Spinocerebellar Ataxia Type 1 (SCA1) is an autosomal dominant late onset neurodegenerative disease caused by an expanded polyglutamine tract in ataxin-1. Here, we compared the protective effects of overexpressing ataxin-1-like using recombinant AAVs, or reducing expression of mutant ataxin-1 using virally delivered RNA interference (RNAi), in a transgenic mouse model of SCA1. For the latter, we used an artificial microRNA (miR) design that optimizes potency, efficacy and safety to suppress ataxin-1 expression (miS1). Delivery of either ataxin-1-like or miS1 viral vectors to SCA1 mice cerebella resulted in widespread cerebellar Purkinje cell transduction and improved behavioral and histological phenotypes. Our data indicate the utility of either approach as a possible therapy for SCA1 patients.

PMID:
23583610
PMCID:
PMC4173078
DOI:
10.1016/j.nbd.2013.04.003
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center